In this article, we will discuss the above mechanisms, explore the possibility of improving HT patients by interfering with intestinal microbiota, and summarize the level changes of relevant biomarkers in HT patients to discuss the potential as a new diagnosis and treatment marker, such as zonulin protein, inflammatory body, short-chain fatty acid, secondary bile acid, IL-18, and IL-1. The gene discussed is IL1B; the disease is hematocrit.